Global Uveitis Treatment Market to Grow at 4.3% During 2023-2028, Bolstered by Growing Prevalence of Eye Disorders

September 09, 2021 | Healthcare

The latest report by IMARC Group, titled “Uveitis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” finds that the global uveitis treatment market size reached US$ 1.6 Billion in 2022. Uveitis refers to a condition that causes inflammation of the middle layer of tissue in the eyewall uvea. It causes swelling that can damage the eye tissues, leading to poor vision or blindness. Uveitis is mainly caused by autoimmune diseases in which the body attacks itself, causing inflammation, infection and tumor in the eyes or other parts of the body. The treatment for uveitis involves a therapeutic process that can heal the inflammation of the uvea and surrounding tissues. It is treated with the help of drugs such as cycloplegic agents, anti-inflammatory, antimicrobials, as well as immunotherapy and targeted therapies. Uveitis treatment also provides the patient with relief from the pain, prevents further damage of the tissues, and restores vision loss.

Global Uveitis Treatment Market Trends:

The market is driven by the increasing prevalence of uveitis and other infectious eye disorders in individuals. Besides this, the growing awareness regarding the need for proper treatment among patients is also encouraging the adoption of advanced therapeutics. In addition to this, the rising complication associated with uveitis has resulted in increased investment in healthcare, thereby fueling the market growth. Furthermore, individualswith diabetes, eye injuries, cataracts, glaucoma, band keratopathy, and inflammatory disorders are more susceptible to uveitis. As a result, governments of different nations are taking initiatives to accelerate the approval of drugs in the pipeline and new routes of drug administration to improve the efficacy of the drugs. In addition to this, there has been a rise in the number of clinical trials for eye inflammation treatments for refractory posterior and intermediate uveitis across the globe. Nowadays, several leading manufacturers have increased their production capacity of the medication. Moreover, extensive research and development (R&D) activities in the field of ophthalmology have led to the introduction ofadvanced uveitis treatment, creating lucrative opportunities in the market. Looking forward, the market is expected to grow at a CAGR of 4.3% during the forecast period (2023-2028).

Market Summary:

Based on the treatment type, the market has been segmented into corticosteroids, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics.
On the basis of the disease type, the market has been classified into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis.
The market has been categorized based on the cause into infectious and non-infectious.
On the basis of the distribution channel, the market has been segregated into hospital, retail, online, and other pharmacies.
Region-wise, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil Mexico, and others) and Middle East and Africa.
The competitive landscape of the market has been examined, with some of the key players being AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Santen Pharmaceutical Co. Ltd.

Report Scope:

Report Features	Details
Base Year of the Analysis	2022
Historical Period	2017-2022
Forecast Period	2023-2028
Units	US$ Billion
Segment Coverage	Treatment Type, Disease Type, Cause, Distribution Channel, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Uveitis Treatment Market to Grow at 4.3% During 2023-2028, Bolstered by Growing Prevalence of Eye Disorders

Purchase options Year End sale

Single User License ~~$2499~~ $2249
Five User License ~~$3499~~ $2974
Corporate License ~~$4499~~ $3599

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.